Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Validation and refinement of the new high-risk multiple myeloma (HRMM) criteria in relapsed or refractory patients treated with BCMA CAR-T.

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJoshua GustineBPBenjamin Puliafito

Discussion

Loading...

Member takes

Overview

Validation reveals revised HRMM criteria predicts progression-free survival in multiple myeloma patients treated with BCMA CAR-T, indicating need for risk stratification adjustments.

Key Points

  • To assess the revised high-risk multiple myeloma criteria in patients treated with BCMA CAR-T and identify predictors of survival outcomes.
  • Identified consecutive multiple myeloma patients treated with BCMA CAR-T from 2017-2024.
  • Evaluated high-risk criteria including TP53 mutation and extramedullary disease.
  • Used univariable and multivariable hazard regression models to identify predictors of progression-free and overall survival.
  • 46% of patients met revised criteria for high-risk multiple myeloma.
  • Median progression-free survival for all patients was 15 months; overall survival was 42 months.
  • Patients with high-risk criteria had significantly shorter progression-free and overall survival compared to standard-risk patients.

Cite This Study

Gustine et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0achttps://doi.org/10.1182/blood-2025-2243
View Full Paper
Ask AI
Bookmark
Share